Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia

Recruiting

• Conditions: Acute myeloid leukemia; AML; 10024324

• Registration Number: NL-OMON52290
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 151

Inclusion Criteria

- Patient with:
o a diagnosis of AML and related precursor neoplasms according to WHO 2008
classification (excluding acute promyelocytic leukemia) including secondary AML
(after an antecedent hematological disease (e.g. MDS) and therapy-related AML),
or
o acute leukemia*s of ambiguous lineage according to WHO 2008 or
o a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score
> 4.5
- Treated according to HOVON clinical trials
- Age 18 yr or older
- A bone marrow aspiration has been scheduled
- WHO performance status 0, 1 or 2
- Written informed consent

Exclusion Criteria

- Acute promyelocytic leukemia
- Pregnant or lactating females
- Unwilling or not capable to use effective means of birth control

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is to compare the prognostic value of MRD in peripheral<br /><br>blood and bone marrow.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary outcome measure is the amount of leukemic stem cells (LSC) in<br /><br>bone marrow and peripheral blood and the concordance between MRD in PB and BM.</p><br>